83 research outputs found
Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma
Critical Review of Protease- Treated Red Cell Tests for the Detection of Irregular Blood Group Antibodies during Pregnancy
329: VB TCR usage and Treg CD4+CD25+CTLA4+/- cells in acute and chronic graft versus host disease, (GVHD), patients submitted to extracorporealphototherapy, (ECP)
ATG-saporin-S6 immunotoxin: a new potent and selective drug to eliminate activated lymphocytes and lymphoma cells.
Involvement of the phosphoinositide 3-kinase/Akt signaling pathway in the resistance to therapeutic treatments of human leukemias
A major factor undermining successful
cancer treatment is the occurrence of resistance to
conventional treatments such as chemotherapy and
ionizing radiation. Evidence accumulated over the recent
years has indicated the phosphoinositide 3-kinase/Akt
signal transduction pathway as one of the major factors
implicated in cancer resistance to conventional therapies.
Indeed, the phosphoinositide 3-kinase/Akt axis regulates
the expression and/or function of many anti-apoptotic
proteins which strongly contributes to cancer cell
survival. As a result, small molecules designed to
specifically target key components of this signaling
network are now being developed for clinical use as
single therapeutic agents and/or in combination with
other forms of therapy to overcome resistance. Initially,
the phosphoinositide 3-kinase/Akt signal transduction
pathway has been mainly investigated in solid tumors.
Recently, however, this network has also been
recognized as an important therapeutic target in human
leukemias. Specific inhibition of this signalling pathway
may be a valid approach to treat these diseases and
increase the efficacy of standard types of therapy
- …